pCR of 37 percent for topical imiquimod in lentigo maligna

October 21, 2016

(HealthDay)—For patients with lentigo maligna (LM) in-situ melanoma, topical imiquimod has a pathological complete regression (pCR) rate of 37 percent, according to a study published online Oct. 6 in the British Journal of Dermatology.

Jeremy R. Marsden, M.D., from the University Hospital Birmingham NHS Foundation Trust in the United Kingdom, and colleagues estimated pCR for LM following imiquimod in a single-arm phase II trial. Data were included for 60 imiquimod applications over 12 weeks for LM, then radical resection.

The researchers found that the pCR rate was 37 percent (10/27). Twelve of 28 patients had clinical complete remission plus negative biopsies, of whom seven out of 11 had pCR on subsequent surgery. The median dose intensity was 86.7 percent. If the cure rate for imiquimod was 80 percent, eight of 16 surveyed patients preferred primary imiquimod over surgery compared with four of 16 patients if the cure rate was ≤50 percent.

"The pCR rate was insufficient to justify phase III investigation of imiquimod versus surgery. Clinical complete response and negative targeted biopsies left uncertainty regarding pathological clearance," the authors write. "Some patients would trade less aggressive treatment of LM against efficacy."

Explore further: Cryotherapy plus imiquimod active in cutaneous melanoma mets

More information: Full Text (subscription or payment may be required)

Related Stories

Cryotherapy plus imiquimod active in cutaneous melanoma mets

December 21, 2015
(HealthDay)—Cryotherapy combined with topical imiquimod 5 percent is an active treatment for locoregional cutaneous metastases of melanoma (LCMM), according to research published online Dec. 12 in the Journal of Dermatology.

Intralesional IL-2 promising for cutaneous melanoma metastases

September 23, 2015
(HealthDay)—Patients with cutaneous melanoma metastases have excellent response to intralesional interleukin 2 (IL-2) administered concomitantly with topical imiquimod and a retinoid cream, according to a case series published ...

Topical skin creams effective to treat superficial basal cell carcinoma

June 2, 2016
Investigators report on three-year follow-up of superficial BCC patients treated topically with non-surgical, noninvasive therapies in the Journal of Investigative Dermatology

Novel mechanisms of action discovered for skin cancer medication Imiquimod

October 20, 2016
Imiquimod is a medication successfully used in the treatment of skin diseases. In addition to its known mechanism of action, it also triggers other processes in the body. Scientists at the Technical University of Munich (TUM) ...

Common therapies for basal cell carcinoma offer similar survival

May 25, 2012
(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published online May ...

New combination treatment effective against melanoma skin

August 11, 2015
In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.

Recommended for you

Sugar supplement slows tumor growth and can improve cancer treatment

November 21, 2018
Mannose sugar, a nutritional supplement, can both slow tumour growth and enhance the effects of chemotherapy in mice with multiple types of cancer.

New mechanism controlling the master cancer regulator uncovered

November 21, 2018
Who regulates the key regulator? The Research Center for Molecular Medicine of the Austrian Academy of Sciences reports online in the journal Science about a newly discovered mechanism by which RAS proteins, central to cancer ...

Researchers stop spread of cancer in mice by blocking specific molecules

November 21, 2018
Melanoma skin cancer tumors grow larger and are more likely to metastasize due to interactions between a pair of molecules, according to experiments in mice and human cells. The results may restore the potential for a type ...

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.